Why the study?
Does a verapamil SR strategy reduce the first occurrence of death, nonfatal MI, or nonfatal stroke compared to an atenolol strategy in patients with CAD and hypertension?
Does a verapamil SR strategy reduce the first occurrence of death, nonfatal MI, or nonfatal stroke compared to an atenolol strategy in patients with CAD and hypertension?
In patients with CAD and hypertension, a verapamil SR-based strategy showed no difference in the primary composite outcome of death, nonfatal MI, or nonfatal stroke compared to an atenolol-based strategy.
Verapamil SR and atenolol strategies yield equivalent primary outcomes in CAD with hypertension; confirms comparable efficacy of these approaches for event reduction.
The INternational VErapamil SR/trandolapril STudy (INVEST) randomized 22,576 CAD, hypertension patients to a verapamil SR (Ve) or atenolol (At) strategy. Flexible dose titration and addition of trandolapril (T) and/or HCTZ targeted BP control and organ protection. There was no difference by strategy for primary outcome (PO; first occurrence of death, nonfatal MI, or nonfatal stroke). An exploratory method was developed to analyze effect of drug-dose combinations on the PO.
No takes yet. Share an insight, caveat, or question.
ELLIOTT et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: